Document Detail


An RCT on the effects of topical CGP on surgical wound appearance and residual scarring in bilateral total-knee arthroplasty patients.
MedLine Citation:
PMID:  22240886     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To test the hypothesis that topically applied calcium glycerophosphate (CGP) would improve the appearance of the wound following bilateral knee replacement.
METHOD: Healthy patients, aged 45-75 years, scheduled for bilateral total-knee replacement surgery were recruited into the study. One knee was randomly assigned to the treatment group, while the contralateral knee was designated the control (standard care). Subjects were instructed to apply a preparation of 10% CGP in an aqueous lotion to the treated knee once daily for 42 days, starting at the third postoperative day. Functional sealing and cosmetic appearance of the incision were evaluated by two surgeons by direct examination of the patient and then by two experienced assessors from photographs. The investigators qualitatively scored the intensity and extent of erythema along the incision and over the entire knee, the appearance of visible oedema along the incision and over the knee, and the overall clinical impression of wound healing. All four assessors were blinded to the subjects' allocation and the latter two assessors to the initial investigators' assessments. Subjects were also followed up for an additional 46 weeks, giving a total study duration of 12 months.
RESULTS: Twenty patients completed the study. Statistical analysis showed that both the area and intensity of erythema along the incision were significantly reduced in the treated vs untreated knee over the entire study period. The analysis further showed that treatment significantly reduced oedema, both along the incision and across the entire knee. The differences were most marked at the seventh postoperative day and diminished with time. No adverse effects were observed for any patient, in either treated or untreated knees.
CONCLUSION: These data demonstrate that postoperative application of 10% CGP could improve the appearance of the wound following total knee arthroplasty.
Authors:
A Ong; F Orozco; E S Sheikh; C Anmuth; A Alfaro; R Kathrins; G L Grove; C Zerweck; A M Madden; R Raspa; M T Weis
Related Documents :
11584396 - Aortopexy in esophageal atresia: long-term experience of a parent support group.
8939836 - Immediate and delayed effects of laparoscopic nissen fundoplication on pulmonary function.
6781426 - The management of nonmalignant intrathoracic esophageal perforations.
8100646 - Chronic pulmonary aspiration in children.
25066626 - Spinal growth modulation with posterior unilateral elastic tether in immature swine model.
12595766 - Comprehensive deep venous thrombosis prevention strategy after total-knee arthroplasty.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of wound care     Volume:  20     ISSN:  0969-0700     ISO Abbreviation:  J Wound Care     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2012-01-13     Completed Date:  2012-02-21     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  9417080     Medline TA:  J Wound Care     Country:  England    
Other Details:
Languages:  eng     Pagination:  592-8     Citation Subset:  N    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Aged
Arthroplasty, Replacement, Knee*
Cicatrix / prevention & control
Erythema / prevention & control
Female
Glycerophosphates / administration & dosage*
Humans
Knee Joint / physiopathology
Male
Middle Aged
Pain Measurement
Range of Motion, Articular
Wound Healing / drug effects*,  physiology
Chemical
Reg. No./Substance:
0/Glycerophosphates

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ecthyma gangrenosum in a premature low-birth-weight newborn.
Next Document:  Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III...